Jia Li1, Liu Rong2, Ran Cui3, Jiaqi Feng1, Yuyang Jin1, Xiaoxiang Chen1, Renying Xu4. 1. Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 2. Department of Critical Care Medicine, Shanghai Jiao Tong University School of Medicine Affiliated Shanghai General Hospital, Shanghai, China. 3. Department of Rheumatology and Immunology, Shanghai Jiao Tong University School of Medicine Affiliated Six People's Hospital, Shanghai, China. 4. Department of Clinical Nutrition, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Abstract
BACKGROUND: Biomarkers to prognosticate the outcomes and guide the treatment of patients with severe coronavirus disease 2019 (COVID-19) are currently required. We aimed to investigate whether the dynamic variation of cytokines was associated with the survival of patients admitted to the intensive care unit (ICU). METHODS: A retrospective study was performed on 40 patients with COVID-19 admitted to the ICU in Wuhan, China. Demographic, clinical, and laboratory variables were collected, and serum cytokines were kinetically assessed. A multivariable-adjusted generalized linear regression model was used to analyze the differences in serum cytokine levels between survivors and non-survivors. RESULTS: Among the 40 patients included, we found a positive correlation between multiple cytokines. Serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor alpha (TNFα) in non-survivors were consistently elevated compared to those in the survivors. Kinetic variations in IL-6, IL-8, and IL-10 were associated with a fatal outcome in patients with severe COVID-19, independent of sex, age, absolute lymphocyte count, direct bilirubin, hypertension, chronic obstructive pulmonary disease, and cancer as well as the use of glucocorticoids and tocilizumab. CONCLUSIONS: Dynamic changes in serum IL-6, IL-8, and IL-10 levels were associated with survival in patients in the ICU, and could serve as a predictive biomarker to determine the therapeutic options for patients with severe COVID-19.
BACKGROUND: Biomarkers to prognosticate the outcomes and guide the treatment of patients with severe coronavirus disease 2019 (COVID-19) are currently required. We aimed to investigate whether the dynamic variation of cytokines was associated with the survival of patients admitted to the intensive care unit (ICU). METHODS: A retrospective study was performed on 40 patients with COVID-19 admitted to the ICU in Wuhan, China. Demographic, clinical, and laboratory variables were collected, and serum cytokines were kinetically assessed. A multivariable-adjusted generalized linear regression model was used to analyze the differences in serum cytokine levels between survivors and non-survivors. RESULTS: Among the 40 patients included, we found a positive correlation between multiple cytokines. Serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor alpha (TNFα) in non-survivors were consistently elevated compared to those in the survivors. Kinetic variations in IL-6, IL-8, and IL-10 were associated with a fatal outcome in patients with severe COVID-19, independent of sex, age, absolute lymphocyte count, direct bilirubin, hypertension, chronic obstructive pulmonary disease, and cancer as well as the use of glucocorticoids and tocilizumab. CONCLUSIONS: Dynamic changes in serum IL-6, IL-8, and IL-10 levels were associated with survival in patients in the ICU, and could serve as a predictive biomarker to determine the therapeutic options for patients with severe COVID-19.
Authors: Maria Candida Cesta; Mara Zippoli; Carolina Marsiglia; Elizabeth Marie Gavioli; Flavio Mantelli; Marcello Allegretti; Robert A Balk Journal: Front Pharmacol Date: 2022-01-12 Impact factor: 5.810
Authors: Alejandro Escobar; Felipe E Reyes-López; Mónica L Acevedo; Luis Alonso-Palomares; Fernando Valiente-Echeverría; Ricardo Soto-Rifo; Hugo Portillo; Jimena Gatica; Ivan Flores; Estefanía Nova-Lamperti; Carlos Barrera-Avalos; María Rosa Bono; Leonardo Vargas; Valeska Simon; Elias Leiva-Salcedo; Cecilia Vial; Juan Hormazabal; Lina Jimena Cortes; Daniel Valdés; Ana M Sandino; Mónica Imarai; Claudio Acuña-Castillo Journal: Front Immunol Date: 2022-01-31 Impact factor: 7.561
Authors: Julie C Wilson; David Kealy; Sally R James; Tobias Plowman; Katherine Newling; Christopher Jagger; Kara Filbey; Elizabeth R Mann; Joanne E Konkel; Madhvi Menon; Sean B Knight; Angela Simpson; Aliya Prihartadi; Greg Forshaw; Neil Todd; David R A Yates; John R Grainger; Tracy Hussell; Paul M Kaye; Nathalie Signoret; Dimitris Lagos Journal: iScience Date: 2021-12-20